Construction and characterisation of O139 cholera vaccine candidates

Vaccine

Volumn 21, Issue 11-12, 2003, Pages 1282-1291

  Ledón, Talena ^a   Valle, Edgar ^a   Valmaseda, Tania ^b   Cedré, Barbara ^b   Campos, Javier ^a   Rodríguez, Boris L ^a   Marrero, Karen ^a   García, Hilda ^b   García, Luis ^b   Fando, Rafael ^a  

^a NATL CENTER FOR SCIENTIFIC RESEARCH   (Cuba)

^b FINLAY INSTITUTE   (Cuba)

Author keywords

hapA mutants; O139 cholera vaccine; thyA mutants

Indexed keywords

CHOLERA VACCINE; GLUCAN SYNTHASE; HEMAGGLUTININ; LIVE VACCINE; PROTEINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM MUTANT; CHOLERA; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFICACY; DRUG SAFETY; ENVIRONMENT; GENE INSERTION; GENE LOCUS; GENE MUTATION; GENETIC MANIPULATION; IMMUNE RESPONSE; IMMUNOGENICITY; INFECTION PREVENTION; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RABBIT; SAFETY; VIBRIO CHOLERAE;

ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL CAPSULES; CELLULASE; CHOLERA; CHOLERA TOXIN; CHOLERA VACCINES; CLOSTRIDIUM; DRUG RESISTANCE; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GENES, SYNTHETIC; HEMAGGLUTINATION TESTS; IMMUNOGLOBULIN G; METALLOENDOPEPTIDASES; MUTAGENESIS, INSERTIONAL; O ANTIGENS; RABBITS; SAFETY; STREPTOMYCIN; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION; VIBRIO CHOLERAE O139;

EID: 0037424118     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00412-7     Document Type: Article

References (53)

1. Ramamurthy T., Garg S., Sharma R.et al. Emergence of novel strain of Vibrio cholerae with epidemic potential in southern and eastern India. Lancet. 341:1993;703-704.
2. Mekalanos J.J., Sadoff J.C. Cholera vaccines: fighting an ancient scourge. Science. 265:1994;1387-1389.
3. Coster T.S., Killing K.P., Waldor M.K.et al. Safety, immunogenicity and efficacy of live attenuated Vibrio cholerae O139 vaccine prototype. Lancet. 345:1995;949-952.
4. Benítez J.A., García L., Silva A. Preliminary assessment of the safety and immunogenicity of a new CTXΦ-negative, hemagglutinin/protease-defective El Tor candidate cholera vaccine strain. Infect. Immun. 67(2):1999;539-545.
5. Kenner J.R., Coster T.S., Taylor D.N.et al. Peru 15, an improve live attenuated oral vaccine candidate for Vibrio cholerae O1. J. Infect. Dis. 172:1995;1126-1129.
6. Booth B.A., Boesman-Finkelstein M., Finkelstein R.A. Vibrio cholerae soluble hemagglutinin/protease is a metalloenzyme. Infect. Immun. 42:1983;558-560.
7. Häse C.C., Finkelstein R.A. Bacterial extracellular zinc-containing metalloproteases. Microbiol. Rev. 57:1993;823-837.
8. Booth B.A., Boesman-Finkelstein M., Finkelstein R.A. Vibrio cholerae hemagglutinin/protease nicks cholera enterotoxin. Infect. Immun. 45:1984;558-560.
9. Finkelstein R.A., Boesman-Finkelstein M., Holt P. Vibrio cholerae hemagglutinin/lectin/protease hydrolysis fibronectin and ovomucin: F.M. Burnet revisited. Proc. Natl. Acad. Sci. U.S.A. 80:1983;1092-1095.
10. Kimsey H.H., Waldor M.K. Vibrio cholerae hemagglutinin/protease inactivates CTXΦ Infect. Immun. 66(9):1998;4025-4029.
11. Robert A., Silva A., Benítez J.A.et al. Tagging a Vibrio cholerae El Tor candidate vaccine strain by disruption of its hemagglutinin/protease gene using a novel reporter enzyme: Clostridium thermocellum endoglucanase A. Vaccine. 14:1996;1517-1522.
12. Cornet P., Millet J., Beguin P., Aubert J.P. Characterization of two cel (cellulose degrading) genes of Clostridium thermocellum coding for endoglucanases. Biotechnology. 1:1983;589-594.
13. Valle E., Ledón T., Cedré B.et al. Construction and characterization of a non-proliferative El Tor cholera vaccine candidate derived from 638. Infect. Immun. 68(11):2000;6411-6418.
14. Cedré B., García L., García H., Fariñas M., Talavera A., Infante J.F. Intestinal colonisation of the infant mouse model by attenuated and virulent Vibrio cholerae strains. Arch. Med. Res. 29:1998;231-234.
15. Holmgren J., Czerkinsky C. Cholera as a model for research on mucosal immunity and development of oral vaccines. Curr. Opin. Immunol. 4:1992;387-392.
16. Ausubel FM, Brent R, Kingston RE, et al. Short protocols in molecular biology. New York: Wiley; 1995.
17. Simon R., Priefer U., Puhler A. A broad host range mobilization system for in vivo genetic engineering: transposon mutagenesis in gram negative bacteria. Biotechnology. 1:1983;781-791.
18. Miller V.L., Mekalanos J.J. Genetic analysis of the cholera toxin positive regulator toxR. J. Bacteriol. 163:1985;580-585.
19. Benítez J.A., Silva A., Rodríguez B.L.et al. Genetic manipulation of Vibrio cholerae for vaccine development: construction of live attenuated El Tor candidate vaccine strains. Arch. Med. Res. 27(3):1996;275-283.
20. Häse C.C., Finkelstein R.A. Cloning and nucleotide sequence of the Vibrio cholerae hemagglutinin/protease (HA/protease) gene and construction of an HA/protease negative strain. J. Bacteriol. 173:1991;3311-3317.
21. Campos J., Fando R., Silva A., Rodríguez B.L., Benítez J. Replicating function of the RS1 element associated with Vibrio cholerae CTXΦ prophage. FEMS Microbiol. Lett. 164:1998;141-147.
22. Iwanaga M., Yamamoto K., Ichinose Y., Nakasone N., Tanabe M. Culture conditions for stimulating cholera toxin production by Vibrio cholerae O1 El Tor. Microbial. Immunol. 30:1986;1075.
23. Birnboim H.C., Doly J. A rapid alkaline extraction procedure for screening recombinant plasmid DNA. Nucleic Acids Res. 7:1979;1513-1523.
24. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 1989.
25. Chomczynski P., Sacchi N. One-hour downward alkaline capillary transfer for blotting of DNA and RNA. Anal. Biochem. 201:1992;134-139.
26. Holmgren J. Comparison of the tissue receptors for Vibrio cholerae and Escherichia coli enterotoxins by means of gangliosides and natural cholera toxoids. Infect. Immun. 8:1973;851.
27. Häse C.C., Finkelstein R.A. Comparison of the Vibrio cholerae hemagglutinin/protease and the Pseudomonas aeruginosa elastase. Infect. Immun. 58:1990;4011-4015.
28. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 227:1970;680-685.
29. Falero G., Rodríguez B.L., Valmaseda T.et al. Production and characterization of a monoclonal antibody against mannose-sensitive hemagglutinin of Vibrio cholerae. Hybridoma. 17:1998;63-67.
30. Hanne L.F., Finkelstein R.A. Characterization and distribution of the hemagglutinin produced by Vibrio cholerae. Infect. Immun. 36:1982;209-214.
31. Yamamoto T., Kamano T., Uchimura M., Iwanaga M., Yakota T. Vibrio cholerae O1 adherence to villi and lymphoid follicle epithelium: in vitro model using formaline-treated human small intestine and correlation between adherence and cell-associated hemagglutinin levels. Infect. Immun. 56:1988;3241-3250.
32. Mukhopadhyay A.K., Garg S., Mitra R.et al. Temporal shifts in traits of Vibrio cholerae strains isolated from hospitalized patients in Calcutta: a 3-year (1993-1995) analysis. J. Clin. Microbiol. 34:1996;2537-2543.
33. Bascarán V., Hardisson C., Braña A.F. Regulation of extracelular protease production in Streptomyces clavuligerus. Appl. Microbiol. Biotechnol. 34:1990;208-213.
34. Waldor M.K., Mekalanos J.J. Lysogenic conversion by a filamentous phage encoding cholera toxin. Science. 272:1996;1910-1914.
35. Waldor M.K., Rubin E.J., Pearson G.D.N., Kimsey H., Mekalanos J.J. Regulation, replication and integration functions of the Vibrio cholerae CTXΦ are encoded by region RS2. Mol. Microbiol. 24(5):1997;917-926.
36. Finkelstein R.A., Hanne L.F. Purification and characterization of the soluble hemagglutinin (cholera lectin) produced by Vibrio cholerae. Infect. Immun. 36:1982;1199-1208.
37. Nair G.B., Shimada T., Kurazono H.et al. Characterization of phenotypic, serological, and toxigenic traits of Vibrio cholerae O139B. J. Clin. Microbiol. 32:1994;2775-2779.
38. Waldor M.K., Tschape H., Mekalanos J.J. A new type of conjugative transposon encodes resistance to sulfamethoxazole, trimethoprim and streptomycin in Vibrio cholerae O139. J. Bacteriol. 178(14):1996;4157-4167.
39. Young D.B., Broadbent D.A. Biochemical characterization of extracellular proteases from Vibrio cholerae. Infect. Immun. 37:1982;875-883.
40. Bhadra R.K., Roychoudhury S., Banerjee R.K.et al. Cholera toxin (CTX) genetic element in Vibrio cholerae O139. Microbiology. 141:1995;1977-1983.
41. Basu A., Mukhopadhyay A.K., Sharma C.et al. Heterogeneity in the organization of the CTX genetic element in strain of Vibrio cholerae O139 Bengal isolated from Calcutta, India and Dhaka, Bangladesh and its possible link to the dissimilar incidence of O139 cholera in the two locales. Microb. Pathog. 24:1998;175-183.
42. Waldor M.K., Mekalanos J.J. Emergence of a new cholera pandemic: molecular analysis of virulence determinants in Vibrio cholerae O139 and development of a live vaccine prototype. J. Infect. Dis. 170:1994;278-283.
43. Sharma C., Nair G.B., Mukhopadhyay A.K., Bhattacharya S.K., Ghosh R.K., Ghosh A. Molecular characterization of Vibrio cholerae O1 biotype El Tor strains isolated between 1992 and 1995 in Calcutta, India: evidence for the emergence of a new clone of the El Tor biotype. J. Infect. Dis. 175:1997;1134-1141.
44. Clemens J.D., Van Loon F., Sack D.A.et al. Field trial of oral cholera vaccines in Bangladesh: serum vibriocidal and antitoxic antibodies as markers of the risk of cholera. J. Infect. Dis. 163:1991;1235-1242.
45. Kimsey H.H., Waldor M.K. CTXΦ immunity: application in the development of cholera vaccines. PNAS. 95:1998;7035-7039.
46. Losonsky G.A., Yunyongying J., Lim V.et al. Factors influencing vibriocidal immune responses: relevance to understanding immunity to cholera. Infect. Immun. 64(1):1996;10-15.
47. Attridge S.R., Qadri F., Albert M.J., Manning P.A. Susceptibility of Vibrio cholerae O139 to antibody-dependent, complement mediated bacteriolysis. Clin. Diagn. Lab. Immunol. 7(3):2000;444-450.
48. Mekalanos J.J., Waldor M.K., Gardel C.L.et al. Live cholera vaccines: perspectives on their construction and safety. Bull. Inst. Pasteur. 93:1995;255-262.
49. Wu Z., Nybom P., Magnusson K.E. Distinct effects of Vibrio cholerae hemagglutinin/protease on the structure and localization of the tight junction-associated protein occluding and ZO-1. Cell. Microbiol. 2(1):2000;11-17.
50. Mel S.F., Fullner K.J., Wimer-Mackin S., Lencer W., Mekalanos J.J. Association of protease activity in Vibrio cholerae vaccine strains with decreases in transcellular epithelial resistance of polarized T84 intestinal epithelial cells. Infect. Immun. 68(11):2000;6487-6492.
51. Rodríguez B.L., Rojas A., Campos J.et al. Differential interleukin-8 response of intestinal epithelial cell line to reactogenic and non-reactogenic candidate vaccine strains of Vibrio cholerae. Infect. Immun. 69:2001;613-616.
52. Levine M.M., Kaper J.B., Herrington D.et al. Volunteers studies of deletion mutants of Vibrio cholerae O1 prepared by recombinant techniques. Infect. Immun. 56:1988;161-167.
53. Attridge S.R. Thymine auxotrophy as an attenuating marker in Vibrio cholerae. Microb. Pathog. 19:1995;11-18.